skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 3
Patent #:
Issue Dt:
05/29/2007
Application #:
10481033
Filing Dt:
12/16/2003
Publication #:
Pub Dt:
08/12/2004
Inventors:
Tsuyoshi Maekawa, Jun Kunitomo, Hiroyuki Odaka, Hiroyuki Kimura
Title:
FUNCTION REGULATOR FOR RETINOID RELATIVE RECEPTOR
Assignment: 1
Reel/Frame:
015235/0834Recorded: 12/16/2003Pages: 3
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
11/27/2003
Exec Dt:
11/27/2003
Exec Dt:
11/27/2003
Exec Dt:
11/27/2003
Assignee:
1-1, DOSHOMACHI 4-CHOME
CHUO=KU
OSAKA, JAPAN 540-8645
Correspondent:
TAKEDA PHARMACEUTICALS NORTH AMERICA,
INC. - MARK CHAO, PHD, JD
INTELECTUAL PROPERTY DEPARTMENT
475 HALF DAY ROAD, SUITE 500
LINCOLNSHIRE, IL 60069
Assignment: 2
Reel/Frame:
018598/0340Recorded: 12/07/2006Pages: 2
Conveyance:
CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
06/29/2004
Assignee:
1-1, DOSHOMACHI 4-CHOME
CHUO-KU
OSAKA, JAPAN 540-8645
Correspondent:
EDWARDS ANGELL PALMER & DODGE LLP
PO BOX 55874
BOSTON, MA 02205
Assignment: 3
Reel/Frame:
018917/0406Recorded: 06/02/2005Pages: 4
Conveyance:
CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
10/13/2004
Assignee:
1-1, DOSHOMACHI 4-CHOME, CHUO-KU
INTELLECTUAL PROPERTY DEPARTMENT
OSAKA, JAPAN 541-0045
Correspondent:
MARK CHAO, PH.D., JD
INTELLECTUAL PROPERTY DEPARTMENT
TAKEDA PHARMACEUTICALS NORTH AMERICA,INC
475 HALF DAY ROAD
LINCOLNSHIRE, IL 60068

Search Results as of: 04/27/2024 10:41 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT